Literature DB >> 9118313

Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine.

J H Meador-Woodruff1, R E King, S P Damask, K A Bovenkerk.   

Abstract

Dopamine-glutamate interactions within discrete neural circuits are increasingly recognized as potential substrates for dysregulation in schizophrenia, and as a result, potential targets for pharmacological intervention in this illness. We examined the regulation, by haloperidol (2 mg kg-1 day-1) and clozapine (20 mg kg-1 day-1), of the mRNAs encoding the four AMPA receptor subunits (gluR1-gluR4), three low-affinity kainate receptor subunits (gluR5-gluR7), and two high-affinity kainate subunits (KA1 and KA2) in the rat hippocampal formation and associated entorhinal cortex. A complex and differential pattern of AMPA and kainate subunit mRNA regulation by clozapine and haloperidol was observed in this study. Both drugs caused significant alterations of most of these mRNAs, but in a heterogeneous and region-specific fashion. These data suggest that these antipsychotic drugs alter the expression of the genes encoding the subunits that express ionotropic glutamate receptors. Given the importance of glutamatergic mechanisms and the hippocampal formation in schizophrenia, these data suggest a potential substrate for neurotransmitter dysregulation in this illness, as well as a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9118313

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  6 in total

Review 1.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

2.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

Review 3.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

4.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

5.  Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia.

Authors:  Stella Dracheva; William Byne; Benjamin Chin; Vahram Haroutunian
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

Review 6.  What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit.

Authors:  C Barkus; D J Sanderson; J N P Rawlins; M E Walton; P J Harrison; D M Bannerman
Journal:  Mol Psychiatry       Date:  2014-09-16       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.